FOLLOW US

Medical supplies powerhouse Medline Industries Inc. has officially filed for an initial public offering (IPO), signaling its return to the public market four years after a $30 billion private equity buyout by Blackstone, Carlyle Group, and Hellman & Friedman.

The long-anticipated filing — prepared with Simpson Thacher & Bartlett LLP as company counsel and Latham & Watkins LLP advising underwriters — could become one of the largest public offerings in recent years, potentially raising as much as $5 billion, according to research firm Renaissance Capital.

Medline’s Comeback: From Private Equity Giant to Market Titan

Founded in 1966 and headquartered in Northfield, Illinois, Medline has grown into the largest provider of medical-surgical products in the U.S., with a catalog of over 335,000 items ranging from surgical kits to protective apparel.

In its Tuesday filing with the U.S. Securities and Exchange Commission, Medline reported $13.5 billion in net sales and $700 million in net income in the first half of this year. The company said it has maintained 18% compound annual growth since its inception — a rare feat in a sector often defined by narrow margins and heavy competition.

After confidentially submitting IPO paperwork late last year, Medline delayed going public amid market turbulence and tariff-related uncertainty. Now, with renewed momentum — and despite a government shutdown that has slowed SEC operations — the company joins a wave of corporations testing Wall Street’s resilience.

History Repeats: From 1970s Public Offering to Modern Revival

This is not Medline’s first foray into the public market. The company initially went public in 1972, only to go private again in 1977. Decades later, it became one of the most significant leveraged buyouts in history when Blackstone and its partners acquired Medline for over $30 billion in 2021.

If the new IPO proceeds as planned, Medline intends to list shares on the Nasdaq Global Select Market under the ticker symbol “MDLN.”

Legal and Financial Powerhouses Behind the Deal

Medline’s legal team from Simpson Thacher & Bartlett LLP includes Joshua Ford Bonnie, Jonathan R. Ozner, and Katharine L. Thompson.
The underwriters, represented by Latham & Watkins LLP, include Jason M. Licht, Patrick H. Shannon, and Cathy A. Birkeland.

Leading the underwriting syndicate are Goldman Sachs & Co., Morgan Stanley, BofA Securities, and J.P. Morgan, serving as lead book-running managers for what could become the largest healthcare IPO of the decade.

A Strategic Move Amid Industry Consolidation

Medline’s IPO marks a pivotal moment in the healthcare supply sector, as companies race to scale digital capabilities, logistics efficiency, and global reach post-pandemic.

CEO and executives declined to comment, but analysts say the filing reflects renewed investor confidence in the healthcare manufacturing and distribution market — a sector that has proven remarkably resilient in uncertain economic times.

If successful, Medline’s market comeback could reshape investor sentiment across the healthcare supply chain — a signal that one of the industry’s biggest players is once again ready to step into the spotlight.